Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 6/20 | 0.35 |
| ▸ | ACACA | Q13085 | 6/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.33 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.33 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293993 | 0.86 | L3MBTL3 (0.39) | MEN1KMT2AL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL3495073 | 0.84 | HPGD (0.46) | ALDH1A1KDM4EPOLB | |
| SCHEMBL14222611 | 0.82 | KDM4E (0.35) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL16992343 | 0.74 | L3MBTL3 (0.41) | MEN1KMT2AALDH1A1KDM4EL3MBTL3 | |
| SCHEMBL20899058 | 0.73 | USP2 (0.36) | MEN1KMT2AALDH1A1 | |
| SCHEMBL1447288 | 0.72 | CYP3A4 (0.35) | MEN1KMT2AALDH1A1 | |
| SCHEMBL14964764 | 0.72 | CHRM1 (0.43) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL14222041 | 0.70 | EPHX1 (0.43) | ALDH1A1KDM4EPOLB | |
| SCHEMBL2862492 | 0.70 | L3MBTL3 (0.58) | MEN1KMT2AL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL4334091 | 0.70 | L3MBTL3 (0.58) | MEN1KMT2AL3MBTL3L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100093777-A1 | SPIRO-RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2128163-A1 | SPIRO-RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | MEN1 4260/4885KMT2A 3284/4885ALDH1A1 772/4885 |
| US-20100093777-A1 | SPIRO-RING COMPOUND | ACACA, PC, ACACB | MEN1 2745/4885KMT2A 2374/4885ALDH1A1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.